Several in vitro studies have used CRISPR-based cleavage approaches to disrupt mutant KRAS, and have demonstrated the potential of this system for treating patients with KRAS mutant cancers [61,62,63,64,65,66]. The gene discussed is KRAS; the disease is cancer.